8 January 2024
PDMR Share Dealing
Graft Polymer (UK) Plc ("Company") announces that on 4 January 2024, ordinary shares of £0.001 each in the Company ("Ordinary Shares") were disposed of by a person discharging managerial responsibility ("PDMR") in the Company as listed below.
| Name | Role | Nature of transaction | Number of Ordinary Shares |
| Victor Bolduev | Chief Executive Officer, Director | Transfer of Ordinary Shares | 10,750,000 |
It is further announced that on 4 January 2024, Ordinary Shares were subscribed for (subject to various conditions being met, including approval by the FCA, and publication, of a prospectus ("Conditions")) ("Subscription") by certain PDMRs and persons closely associated with PDMRs as listed below.
| Name | Role | Nature of transaction | Number of Ordinary Shares |
| Victor Bolduev | Chief Executive Officer, Director | Conditional subscription for Ordinary Shares | 22,529,1661 |
| Roby Zomer | Chairman, Director | Conditional subscription for Ordinary Shares | 11,111,000 |
| Yifat Steuer | Chief Financial Officer, Director | Conditional subscription for Ordinary Shares | 11,711,167 |
| Pavel Kobzev | Chief Marketing Officer, Director | Conditional subscription for Ordinary Shares | 8,694,0002 |
| Alexander Brooks | Director | Conditional subscription for Ordinary Shares | 2,810,667 |
| Anthony Eastman | Company Secretary | Conditional subscription for Ordinary Shares | 2,810,6673 |
1 Of which 11,760,333 Ordinary Shares were subscribed for by Polymer Innovations Inc., a company controlled by Victor Bolduev.
2 Of which 5,675,167 Ordinary Shares were subscribed for by MSW Ltd, a company controlled by Pavel Kobzev.
3 These Ordinary Shares were subscribed for by Tournesol Consulting Ltd, a company controlled by Anthony Eastman.
A further announcement is expected to be made upon the Conditions having been met.
About Graft Polymer
Graft Polymer is a London Stock Exchange listed company (GPL.L) with a cutting-edge, research and development (R&D) and manufacturing facility based in Slovenia which has already introduced more than 50 products to the market. The core business of the Group comprises polymer modification and drug delivery system developments. The Group has developed a proprietary set of polymer modification technologies which uses recycled raw materials and a closed loop system to reduce waste. Graft Polymer's technology can improve existing products and processing methodologies by enhancing performance, simplifying manufacturing, reducing material consumption, widening the choice of feedstocks, and reducing costs.
Graft Polymer has three divisions: polymer modification; IP for Bio/Pharma applications including a drug delivery system (Graft Bio) and the Group's food supplement division. A significant milestone was reached in May 2022 when the Slovenian manufacturing facility was granted a Hazard Analysis and Critical Control Point (HACCP) Certificate. The HACCP Certificate allows it to enter the lucrative Business-to-Consumer market and commercialise its IP for bio/pharma applications, developing active pharmaceutical ingredients and drug delivery platforms for use in the food supplement market, thereby introducing a further revenue stream to its business.
Environment, Social and Governance is at the forefront of the Group's strategy and the facility in Slovenia has been granted ISO 14001 accreditation in recognition of the environmental management systems in place to reduce waste. Graft Polymer only uses REACH and ROHS certificated raw materials instead of toxic raw materials, and its extensive R&D programme has also developed specialised recycling polymer additives which increases the strength of recycled blends and plastic products whilst also reducing plastic waste by between 40 and 50 per cent.
For further information, visit www.graftpolymer.com, follow on Twitter @PolymerLtd or contact:
Graft Polymer (UK) Plc
Roby Zomer, Non-Executive Chairman info@graftpolymer.com
Yifat Steuer, CFO and Executive Director
Notification of dealings in shares by PDMRs of the Company:
| 1. | Details of PDMR / PDMR Associate | |
| (a) | Name | Victor Bolduev |
| (b) | Position / status | Chief Executive Officer, Director |
| (c) | Initial notification / amendment | Initial notification |
| 2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| (d) | Description of the financial instrument | Ordinary Shares in Graft Polymer (UK) Plc |
| (e) | Nature of the transaction | Disposal of Ordinary Shares |
| (f) | Price(s) and volume(s) | Price per Ordinary Share: 0.6 pence Volume: 10,750,000
|
| (g) | Aggregated information Aggregated volume Price | n/a
|
| (h) | Date of the transaction | 4 January 2024 |
| (i) | Place of the transaction | London, United Kingdom |
| 1. | Details of PDMR / PDMR Associate | |
| (a) | Name | Victor Bolduev |
| (b) | Position / status | Chief Executive Officer, Director |
| (c) | Initial notification / amendment | Initial notification |
| 2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| (d) | Description of the financial instrument | Ordinary Shares in Graft Polymer (UK) Plc |
| (e) | Nature of the transaction | Subscription of Ordinary Shares (subject to the Conditions, as defined above, being met) |
| (f) | Price(s) and volume(s) | Price per Ordinary Share: 0.6 pence Volume: 10,768,833
|
| (g) | Aggregated information Aggregated volume Price | n/a
|
| (h) | Date of the transaction | 4 January 2024 |
| (i) | Place of the transaction | London, United Kingdom |
| 1. | Details of PDMR / PDMR Associate | |
| (a) | Name | Polymer Innovations Inc. |
| (b) | Position / status | Company controlled by Victor Bolduev |
| (c) | Initial notification / amendment | Initial notification |
| 2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| (d) | Description of the financial instrument | Ordinary Shares in Graft Polymer (UK) Plc |
| (e) | Nature of the transaction | Conditional subscription for Ordinary Shares |
| (f) | Price(s) and volume(s) | Price per Ordinary Share: 0.6 pence Volume: 11,760,333
|
| (g) | Aggregated information Aggregated volume Price | n/a
|
| (h) | Date of the transaction | 4 January 2024 |
| (i) | Place of the transaction | London, United Kingdom |
| 1. | Details of PDMR / PDMR Associate | |
| (a) | Name | Roby Zomer |
| (b) | Position / status | Chairman, Director |
| (c) | Initial notification / amendment | Initial notification |
| 2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| (d) | Description of the financial instrument | Ordinary Shares in Graft Polymer (UK) Plc |
| (e) | Nature of the transaction | Conditional subscription for Ordinary Shares |
| (f) | Price(s) and volume(s) | Price per Ordinary Share: 0.6 pence Volume: 11,111,000
|
| (g) | Aggregated information Aggregated volume Price | n/a
|
| (h) | Date of the transaction | 4 January 2024 |
| (i) | Place of the transaction | London, United Kingdom |
| 1. | Details of PDMR / PDMR Associate | |
| (a) | Name | Yifat Steuer |
| (b) | Position / status | Chief Financial Officer, Director |
| (c) | Initial notification / amendment | Initial notification |
| 2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| (d) | Description of the financial instrument | Ordinary Shares in Graft Polymer (UK) Plc |
| (e) | Nature of the transaction | Conditional subscription for Ordinary Shares |
| (f) | Price(s) and volume(s) | Price per Ordinary Share: 0.6 pence Volume: 11,711,167
|
| (g) | Aggregated information Aggregated volume Price | n/a
|
| (h) | Date of the transaction | 4 January 2024 |
| (i) | Place of the transaction | London, United Kingdom |
| 1. | Details of PDMR / PDMR Associate | |
| (a) | Name | Pavel Kobzev |
| (b) | Position / status | Chief Marketing Officer, Director |
| (c) | Initial notification / amendment | Initial notification |
| 2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| (d) | Description of the financial instrument | Ordinary Shares in Graft Polymer (UK) Plc |
| (e) | Nature of the transaction | Conditional subscription for Ordinary Shares |
| (f) | Price(s) and volume(s) | Price per Ordinary Share: 0.6 pence Volume: 3,018,833
|
| (g) | Aggregated information Aggregated volume Price | n/a
|
| (h) | Date of the transaction | 4 January 2024 |
| (i) | Place of the transaction | London, United Kingdom |
| 1. | Details of PDMR / PDMR Associate | |
| (a) | Name | MSW Ltd |
| (b) | Position / status | Company controlled by Pavel Kobzev |
| (c) | Initial notification / amendment | Initial notification |
| 2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| (d) | Description of the financial instrument | Ordinary Shares in Graft Polymer (UK) Plc |
| (e) | Nature of the transaction | Conditional subscription for Ordinary Shares |
| (f) | Price(s) and volume(s) | Price per Ordinary Share: 0.6 pence Volume: 5,675,167
|
| (g) | Aggregated information Aggregated volume Price | n/a
|
| (h) | Date of the transaction | 4 January 2024 |
| (i) | Place of the transaction | London, United Kingdom |
| 1. | Details of PDMR / PDMR Associate | |
| (a) | Name | Alexander Brooks |
| (b) | Position / status | Director |
| (c) | Initial notification / amendment | Initial notification |
| 2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| (d) | Description of the financial instrument | Ordinary Shares in Graft Polymer (UK) Plc |
| (e) | Nature of the transaction | Conditional subscription for Ordinary Shares |
| (f) | Price(s) and volume(s)
| Price per Ordinary Share: 0.6 pence Volume: 2,810,667
|
| (g) | Aggregated information Aggregated volume Price | n/a
|
| (h) | Date of the transaction | 4 January 2024 |
| (i) | Place of the transaction | London, United Kingdom |
| 1. | Details of PDMR / PDMR Associate | |
| (a) | Name | Tournesol Consulting Ltd |
| (b) | Position / status | Company controlled by Anthony Eastman |
| (c) | Initial notification / amendment | Initial notification |
| 2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| (d) | Description of the financial instrument | Ordinary Shares in Graft Polymer (UK) Plc |
| (e) | Nature of the transaction | Conditional subscription for Ordinary Shares |
| (f) | Price(s) and volume(s) | Price per Ordinary Share: 0.6 pence Volume: 2,810,667
|
| (g) | Aggregated information Aggregated volume Price | n/a
|
| (h) | Date of the transaction | 4 January 2024 |
| (i) | Place of the transaction | London, United Kingdom |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.